FundedIQ
Biotechnology

Ahammune Biosciences

Ahammune Biosciences is a drug discovery company founded in 2016 that prioritizes innovation and specializes in creating new therapies for skin conditions caused by immune system dysfunction. Our primary focus at the moment is on Vitiligo, a depigmenting disorder.

www.ahammune.com Pune, India 1-10 employees
Total raised
$5.0M
Rounds
1
Latest
Series A
Sep 2024

Ahammune Biosciences is a drug discovery company founded in 2016 that prioritizes innovation and specializes in creating new therapies for skin conditions caused by immune system dysfunction. Our primary focus at the moment is on Vitiligo, a depigmenting disorder.

Ahammune Biosciences has raised $5.0M across 1 round. Its most recent round was a Series A of $5.0M in Sep 2024. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Sep 25, 2024
Series A
$5.0M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Ahammune Biosciences is featured in

Similar companies

4baseCare

4baseCare offers advanced genomic solutions in precision oncology to assist individuals with cancer. The company emphasizes the use of advanced genomic technologies to deliver individualized treatments for cancer patients. By examining the genetic makeup of cancer patients, 4baseCare strives to pinpoint targeted therapies that are more efficient and less harmful than conventional treatments. Their offerings encompass genomic testing, analysis of data, and personalized treatment suggestions, all aimed at enhancing patient results and aiding healthcare providers in offering precision medicine. 4baseCare works in partnership with hospitals, research organizations, and pharmaceutical firms to advance cancer treatment and research.

Series B $4.0M
Biodimension Technology

Biodimension is offering biofabricated human tissues as an efficient animal alternative testing solutions to pharma companies for more efficient drug screening and toxicity testing. We leverage biofabrication technology to develop our 3D biofabricated human tissue models.

Series Unknown $840k
Pandorum Technologies

Pandorum Technologies Pvt. Ltd. is a Bangalore based biotechnology company with focus on tissue engineering and regenerative medicine. With its distinct synergy of life science, engineering and clinical competences, the company designs and manufactures three dimensional functional human tissues; intended for medical research and therapeutics. Pandorum Technologies is supported by the Biotechnology Industry Research Assistance Council, Department of Biotechnology, GoI. Pandorum’s labs are presently located in the Center for Cellular and Molecular Platforms, National Centre for Biological Sciences campus, Bengaluru, and in the Bangalore Bioinnovation Centre, Biotech Park, Electronics City Phase 1, Bengaluru.

Series B $18.0M
PlasmaGen Biosciences

PlasmaGen BioSciences is an Indian Bio-pharmaceutical organization specializing exclusively in Plasma Protein Therapy. Headquartered in Bangalore- India, PlasmaGen has been making every effort in the domain of Plasma product Industry and has become an Imperative one stop destination for the medical fraternity for most of the plasma products need. They have a basket of plasma products and the widest range of immunoglobulins in India catering to the requisites of various realms viz. Haematology, Oncology, Immunology, Paediatrics, Rheumatology, Dermatology and Neurology.

Series Unknown $16.8M
Cellarim Labs

Cellarim is at the forefront of the biomanufacturing revolution. As a pioneer in the biotechnology business, we specialize in producing high-value biomolecules in a sustainable manner using our cutting-edge platform. Our objective is to revolutionize the landscape of biomanufacturing by providing greener, more efficient, and scalable solutions, and we've dedicated ourselves to redefining industry standards, ensuring that our methods are as environmentally friendly as they are effective.

Seed $660k
immunitoAI

ImmunitoAI is a life sciences (biotech) platform that leverages AI to revolutionize antibody discovery & therapeutics.

Series A $6.1M
Eyestem

Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and we have built collaborations with pioneers and leaders in the space. Our long-term vision is to create a global and scalable cell therapy platform to treat incurable diseases. We are developing a cell therapy platform to produce consistent, quality products over the next few years, concentrating on in vitro efficacy and safety.

Series B $10.0M
QRL Bioscience

QRL Bioscience is a science and technology-focused company dedicated to finding solutions for diabetic foot ulcers, B-cell cancer, and hospital infections. They provide treatments for chronic wounds, a remedy for B-cell cancer, and innovative ways to protect against pathogens and avoid infections.

Seed $340k
Ivory

Ivory improves the aging process by promoting sharper thinking and better living. They assist in the early detection of neurodegenerative concerns and give tailored brain health solutions.

Seed $1.0M
Prantae Solutions

Prantae Solutions is a biotechnology company that develops cost-effective technologies for uncommon and overlooked conditions. The company is supported by skilled scientists and staff from reputable institutions and universities, legal experts, medical professionals, and media personnel who share a common goal of improving healthcare options. Their main objective is to reinvest all profits into advancing new technologies and promoting health education in the nation. Established in 2015, the company is based in Bhubaneshwar, Odisha, India.

Seed $580k
ErlySign

ErlySign creates home-based early detection test kits for life-threatening illnesses such as Oral cancer, Uterine cancer, Prostate cancer, Lung Cancer, Breast Cancer, Pancreatic Cancer, and others. By utilizing our advanced prognostics and diagnostics system, we have the ability to identify cancer prior to the emergence of any visible tumor or lesion. To put it simply, our tests can detect cancer at stage 0.

Seed $1.9M
BrainSightAI

BrainSightAI is a software platform that uses MRI technology to improve accuracy in neurological and psychiatric analysis. It aids patients in achieving faster recovery and better health outcomes by moving from educated estimates to data-supported diagnoses and predictions.

Seed $5.0M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.